The American Heart Association and the American College of Cardiology joint guideline addressing cardiovascular evaluation ...

For people having surgery unrelated to their hearts, new guidelines detail how to manage heart and stroke risks before, ...

The American Heart Association and the American College of Cardiology joint guideline addressing cardiovascular evaluation ...

The American Heart Association and the American College of Cardiology joint guideline addressing cardiovascular evaluation ...

SGLT2 inhibitors and dulaglutide are associated with comparable risk for dementia; however, it is uncertain whether these findings generalize to newer GLP-1 RAs.

Recurrent stroke risk was lower among patients with type 2 diabetes who used SGLT2 inhibitors within 3 months of ischemic stroke.

New research analyzing the effects of two drugs used to treat type 2 diabetes indicates a consistent lack of cardiovascular and renal benefits in Black populations.

SGLT2 inhibitors, a class of diabetes drugs, may reduce the risk of Alzheimer’s, vascular dementia, and Parkinson’s disease, ...

In patients with type 2 diabetes, GLP-1 receptor agonists and SGLT2 inhibitors have similar kidney and cardiovascular outcomes. Similar kidney and cardiovascular outcomes are found with glucagon-like ...

A class of drugs used to treat diabetes has been linked to a 20% lower risk of dementia and Parkinson's disease. | ...

New research shows diabetes drugs may significantly reduce the risk of dementia, Alzheimer's, and Parkinson’s disease.

When surveyed, many physicians said the belief that patients had adequate symptom control was why they didn’t add more meds.